INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Semler Scientific Inc.
The investigation concerns whether Semler and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On February 28, 2025, Semler filed its annual report for 2024, in which it disclosed that 'there is a risk that [U.S. Department of Justice ('DOJ')] will file a complaint or complaint in intervention in a civil False Claims Act lawsuit seeking damages.' Semler also disclosed receipt of an initial civil investigative demand from the DOJ in July 2017 regarding Semler's claims for reimbursement related to its peripheral artery disease QuantaFlo device. Semler further stated that it had participated in settlement discussions with the DOJ in February 2025, which were unsuccessful.
On this news, Semler's stock price fell $4.03 per share, or 9.4%, to close at $38.89 per share on March 3, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle PeytonPomerantz LLP
[email protected]
646-581-9980 ext. 7980
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Maxim Group Maintains a Buy Rating on Semler Scientific (SMLR), Sets a $95 PT
Semler Scientific, Inc. (NASDAQ:SMLR) is one of the . Analyst Matthew Galinko of Maxim Group maintained a Buy rating on Semler Scientific, Inc. (NASDAQ:SMLR) on August 6, retaining the price target of $95.00. A doctor in focus surrounded by colleagues in a hospital setting. The analyst told investors that Semler Scientific, Inc. (NASDAQ:SMLR) has exhibited a strong commitment to the accumulation of Bitcoin, with a goal to hold 10,000 BTC by the end of 2025 and considerably more in the following years. He added that Semler Scientific, Inc.'s (NASDAQ:SMLR) ability to raise considerable funds through share issuance further supports this accumulation strategy, suggesting a strong financial strategy. Galinko further stated that Semler Scientific, Inc. (NASDAQ:SMLR) is also expanding its medical technology offerings, especially with the formation of CardioVanta, a subsidiary focused on cardiovascular market opportunities. The expected approval of new diagnostic devices may expand the company's market reach, enhancing its revenue potential. Semler Scientific, Inc. (NASDAQ:SMLR) provides technology and software solutions to improve the clinical effectiveness of healthcare providers. The company's multi-test service platform, WellChec, conducts a comprehensive evaluation of patients for chronic disease, including strokes and heart attacks, through the use of its QuantaFlo product as well as other tests. While we acknowledge the potential of SMLR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Associated Press
20 minutes ago
- Associated Press
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PetMed Express, Inc.
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. ('PetMed' or the 'Company') (NASDAQ: PETS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether PetMed and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On June 10, 2025, PetMed issued a press release 'announc[ing] it is delaying the release of the Company's fourth quarter and fiscal year 2025 earnings release and subsequent conference call, which had been scheduled for June 10, 2025, because the Company requires additional time to complete the year-end audit process.' On this news, PetMed's stock price fell $0.47 per share, or 11.22%, to close at $3.72 per share on June 11, 2025. Then, on July 1, 2025, PetMed announced a delay in the filing of its Annual Report for its 2025 fiscal year, citing, among other things, an internal investigation into revenue recognition. On this news, PetMed's stock price fell $0.05 per share, or 1.51%, to close at $3.27 per share on July 1, 2025. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP
Associated Press
an hour ago
- Associated Press
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ('Ultragenyx' or the 'Company') (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980. The investigation concerns whether Ultragenyx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On July 9, 2025, Ultragenyx and its development partner Mereo BioPharma Group plc issued a press release 'announc[ing] that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis[.]' Following a Data Monitoring Committee meeting, the two companies advised that the final analysis would occur 'around the end of the year.' On this news, Ultragenyx's stock price fell $10.41 per share, or 25.11%, to close at $31.04 per share on July 10, 2025. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP
